CDDO Methyl Ester (bardoxolone methyl) is a semi-synthetic triterpenoid developed from the oleanolic acid scaffold that induces apoptosis and differentiation in tumor cells. Agonist of the KEAP1-Nrf2 pathway, thus inducing expression of antioxidant proteins and protection against oxidative damage from injury and inflammation. Also an antagonist of the NF-kB pro-inflammatory transcription factor. Clinical trials are currently underway for type 2 diabetes treatment, due to its potent antidiabetic activity, but was confirmed to enhance cardiac disease during a phase 2 trial in October 2012.